The Japan Atherosclerosis Society (JAS) has proposed a three-tier risk framework for lipoprotein(a), or Lp(a), calling for more intensive management of modifiable cardiovascular risk factors in people with high levels of the genetically determined risk factor. The recommendations are included…
To read the full story
Related Article
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





